Darolutamide trials for Metastatic Castration-resistant Prostate Cancer

All Darolutamide trials · All Metastatic Castration-resistant Prostate Cancer trials

Phase breakdown

Recruiting trials studying Darolutamide for Metastatic Castration-resistant Prostate Cancer

• A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
  NCT07244341 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 19 locations
• A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
  NCT07723248 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 7 locations
• AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
  NCT07611110 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 132 locations
• Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  NCT06401980 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 13 locations
• Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC
  NCT05762536 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
  NCT05519449 · Phase: Phase 1 · Ages: 18 Years to 100 Years · Sex: Male · 36 locations
• Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
  NCT07142551 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location

Common questions

How many trials study Darolutamide for Metastatic Castration-resistant Prostate Cancer?

7 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.